CIRM Funded Clinical Trials

A Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis

Disease Area:
Multiple Sclerosis
Investigator:
Marco Londei
Institution:
Tr1X Inc.
CIRM Grant:
CLIN2-19848 (Pre-Active)
Award Value:
$8,000,000.00
Trial Sponsor:
Tr1X Inc.
Trial Stage:
Phase 1/2
Trial Status:
Launching
Targeted Enrollment:
N/A